These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 26054751)

  • 1. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
    Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
    Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
    Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
    Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
    Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
    Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
    Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
    Zhou J; Chen J; Yu H
    Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
    Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
    Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
    Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
    Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
    Liu W; Ning J; Li C; Hu J; Meng Q; Lu H; Cai L
    Tumour Biol; 2016 May; 37(5):6331-6. PubMed ID: 26628299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5.
    Liang Y; Xu W; Liu S; Chi J; Zhang J; Sui A; Wang L; Liang Z; Li D; Chen Y; Niu H
    Cell Physiol Biochem; 2018; 45(5):2054-2070. PubMed ID: 29533936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.
    Wu B; Xiong J; Zhou Y; Wu Y; Song Y; Wang N; Chen L; Zhang J
    Arch Biochem Biophys; 2020 Oct; 692():108539. PubMed ID: 32777260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
    Qin Z; Dai L; Trillo-Tinoco J; Senkal C; Wang W; Reske T; Bonstaff K; Del Valle L; Rodriguez P; Flemington E; Voelkel-Johnson C; Smith CD; Ogretmen B; Parsons C
    Mol Cancer Ther; 2014 Jan; 13(1):154-64. PubMed ID: 24140934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
    LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP
    Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
    Ouyang W; Yang C; Zhang S; Liu Y; Yang B; Zhang J; Zhou F; Zhou Y; Xie C
    Int J Oncol; 2013 Feb; 42(2):699-711. PubMed ID: 23258590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X
    Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.